[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592820":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":35,"centralContacts":52,"locations":58,"responsibleParty":210,"collaborators":35,"id":212,"slug":213,"hasResults":214,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":214,"sex":220,"minAge":221,"maxAge":35,"enrollmentInfo":222,"targetDuration":35,"studyType":225,"phases":226,"briefSummary":229,"conditions":230,"keywords":35,"overallStatus":61,"whyStopped":35,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":242},{"fullName":5,"class":6},"Avenzo Therapeutics, Inc.","INDUSTRY",[8,15,20,25],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 1, monotherapy (Part 1A) and food effect","EXPERIMENTAL","Escalating doses of twice daily, oral AVZO-023 in 28-day cycles, with addition of fulvestrant",[13,14],"Drug: Fulvestrant","Drug: AVZO-023",{"label":16,"type":10,"description":17,"interventionNames":18},"Phase 1, combination (Parts 1B)","Escalating doses of twice daily, oral AVZO-023 in combination with once daily, oral AVZO-021 in 28-day cycles, with addition of fulvestrant",[19,13,14],"Drug: AVZO-021",{"label":21,"type":10,"description":22,"interventionNames":23},"Phase 1, combination (Parts 1C)","Escalating doses of twice daily, oral AVZO-023 in combination with once daily, oral AVZO-021, with once daily, oral letrozole in 28-day cycles",[19,24,14],"Drug: Letrozole",{"label":26,"type":10,"description":27,"interventionNames":28},"Phase 2, combination (Cohorts 2A, 2B, 2C, and 2D)","Oral doses of AVZO-023 in 28-day cycles at the RP2D determined in Part 1B\u002F1C, in combination with:\n\n2A) letrozole\n\n2B) fulvestrant\n\n2C) AVZO-021 plus fulvestrant\n\n2D) AVZO-021 plus letrozole",[19,13,24,14],[30,36,42,48],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"DRUG","AVZO-021","AVZO-021 is an oral selective CDK2 inhibitor",[16,21,26],null,{"type":31,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"Fulvestrant","Antineoplastic agent, estrogen receptor antagonist",[16,9,26],[41],"Faslodex",{"type":31,"name":43,"description":44,"armGroupLabels":45,"otherNames":46},"Letrozole","Antineoplastic agent, aromatase inhibitor",[21,26],[47],"Femara",{"type":31,"name":49,"description":50,"armGroupLabels":51,"otherNames":35},"AVZO-023","AVZO-023 is an oral selective CDK4 inhibitor",[16,21,9,26],[53],{"name":54,"role":55,"phone":56,"phoneExt":35,"email":57},"Medical Information","CONTACT","(858) 239-2944","ClinicalTrials@avenzotx.com",[59,76,83,94,105,115,126,136,147,157,168,179,189,199],{"facility":60,"status":61,"city":62,"state":63,"zip":64,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":72,"contacts":73},"Avenzo Therapeutics Recruiting Site","RECRUITING","Los Angeles","California","90025","United States","US",{"type":68,"coordinates":69},"Point",[70,71],-118.24368,34.05223,{"lat":71,"lon":70},[74],{"name":75,"role":55,"phone":35,"phoneExt":35,"email":35},"Avenzo Therapeutics",{"facility":60,"status":61,"city":62,"state":63,"zip":77,"country":65,"countryCode":66,"cosmosGeoPoint":78,"geoPoint":80,"contacts":81},"90095",{"type":68,"coordinates":79},[70,71],{"lat":71,"lon":70},[82],{"name":75,"role":55,"phone":35,"phoneExt":35,"email":35},{"facility":60,"status":61,"city":84,"state":85,"zip":86,"country":65,"countryCode":66,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"New Haven","Connecticut","06519",{"type":68,"coordinates":88},[89,90],-72.92816,41.30815,{"lat":90,"lon":89},[93],{"name":75,"role":55,"phone":35,"phoneExt":35,"email":35},{"facility":60,"status":61,"city":95,"state":96,"zip":97,"country":65,"countryCode":66,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Orlando","Florida","32827",{"type":68,"coordinates":99},[100,101],-81.37924,28.53834,{"lat":101,"lon":100},[104],{"name":75,"role":55,"phone":35,"phoneExt":35,"email":35},{"facility":60,"status":61,"city":106,"state":96,"zip":107,"country":65,"countryCode":66,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"Sarasota","34232",{"type":68,"coordinates":109},[110,111],-82.53065,27.33643,{"lat":111,"lon":110},[114],{"name":75,"role":55,"phone":35,"phoneExt":35,"email":35},{"facility":60,"status":61,"city":116,"state":117,"zip":118,"country":65,"countryCode":66,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"Boston","Massachusetts","02215",{"type":68,"coordinates":120},[121,122],-71.05977,42.35843,{"lat":122,"lon":121},[125],{"name":75,"role":55,"phone":35,"phoneExt":35,"email":35},{"facility":60,"status":61,"city":127,"state":127,"zip":128,"country":65,"countryCode":66,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"New York","10016",{"type":68,"coordinates":130},[131,132],-74.00597,40.71427,{"lat":132,"lon":131},[135],{"name":75,"role":55,"phone":35,"phoneExt":35,"email":35},{"facility":60,"status":61,"city":137,"state":138,"zip":139,"country":65,"countryCode":66,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"Cleveland","Ohio","44106",{"type":68,"coordinates":141},[142,143],-81.69541,41.4995,{"lat":143,"lon":142},[146],{"name":75,"role":55,"phone":35,"phoneExt":35,"email":35},{"facility":60,"status":61,"city":148,"state":138,"zip":149,"country":65,"countryCode":66,"cosmosGeoPoint":150,"geoPoint":154,"contacts":155},"Columbus","43221",{"type":68,"coordinates":151},[152,153],-82.99879,39.96118,{"lat":153,"lon":152},[156],{"name":75,"role":55,"phone":35,"phoneExt":35,"email":35},{"facility":60,"status":61,"city":158,"state":159,"zip":160,"country":65,"countryCode":66,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"Nashville","Tennessee","37203",{"type":68,"coordinates":162},[163,164],-86.78444,36.16589,{"lat":164,"lon":163},[167],{"name":75,"role":55,"phone":35,"phoneExt":35,"email":35},{"facility":60,"status":61,"city":169,"state":170,"zip":171,"country":65,"countryCode":66,"cosmosGeoPoint":172,"geoPoint":176,"contacts":177},"Fort Worth","Texas","76104",{"type":68,"coordinates":173},[174,175],-97.32085,32.72541,{"lat":175,"lon":174},[178],{"name":75,"role":55,"phone":35,"phoneExt":35,"email":35},{"facility":60,"status":61,"city":180,"state":170,"zip":181,"country":65,"countryCode":66,"cosmosGeoPoint":182,"geoPoint":186,"contacts":187},"Houston","77030",{"type":68,"coordinates":183},[184,185],-95.36327,29.76328,{"lat":185,"lon":184},[188],{"name":75,"role":55,"phone":35,"phoneExt":35,"email":35},{"facility":60,"status":61,"city":190,"state":170,"zip":191,"country":65,"countryCode":66,"cosmosGeoPoint":192,"geoPoint":196,"contacts":197},"San Antonio","78229",{"type":68,"coordinates":193},[194,195],-98.49363,29.42412,{"lat":195,"lon":194},[198],{"name":75,"role":55,"phone":35,"phoneExt":35,"email":35},{"facility":60,"status":61,"city":200,"state":201,"zip":202,"country":65,"countryCode":66,"cosmosGeoPoint":203,"geoPoint":207,"contacts":208},"Fairfax","Virginia","22031",{"type":68,"coordinates":204},[205,206],-77.30637,38.84622,{"lat":206,"lon":205},[209],{"name":75,"role":55,"phone":35,"phoneExt":35,"email":35},{"type":211,"investigatorFullName":35,"investigatorTitle":35,"investigatorAffiliation":35,"oldNameTitle":35,"oldOrganization":35},"SPONSOR","100592820","phase-1-orion-1-study-of-avzo-023-as-a-single-agent-and-in-combination-with-avzo-021-andor-endocrine-therapy-in-advanced-solid-tumors-100592820",false,"NCT06998407","ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and\u002For Endocrine Therapy in Advanced Solid Tumors","A Phase 1\u002F2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-023 as a Single Agent, and in Combination With AVZO-021 and\u002For Endocrine Therapy in Patients With Advanced Solid Tumors","AVZO-023-1001","Key Inclusion Criteria:\n\n* Male or female aged ≥ 18 years old at screening with Eastern Cooperative Oncology Group (ECOG) 0-1 and life expectancy \\> 3 months\n* Patients with histologically or cytologically proven advanced malignancies of preferred indications\n* Measurable disease (as assessed by investigator using RECIST v1.1) is preferred in Phase 1 dose escalation, unless otherwise specified in the protocol, and in all patients in Phase 2. Bone only disease is allowed in dose escalation.\n* Agree to provide molecular test report results to confirm eligibility and archival tumor samples and\u002For fresh biopsy, as applicable\n* Adequate renal, liver, and bone marrow function\n\nKey Exclusion Criteria:\n\n* Patients should not have received any prior selective investigational CDK (CDK2, CDK4, CDK2\u002F4, CDK2\u002F4\u002F6) inhibitors\n* Has known active brain metastasis (have either previously untreated intracranial CNS metastasis or previously treated intracranial central nervous system (CNS) metastasis with radiologically documented new or progressing CNS lesions) or leptomeningeal disease\n* Other concurrent invasive malignancy or a prior invasive malignancy for which treatment was completed within 3 years before the first dose on study except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ, or colorectal adenomatous polyps\n* Last anticancer treatment within 2 weeks (4 weeks for biologic, immunotherapy or ADC) or 5 half-lives of the drug, whichever is shorter, prior to first dose on study\n* Major surgery within 4 weeks prior to first dose on study\n* Have received radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment, except for patients receiving whole brain radiotherapy, which must be completed at least 4 weeks prior to the first dose of study treatment. Patients must have recovered from all radiation-related toxicities, not require corticosteroids, and not have active radiation pneumonitis\n* Strong or moderate CYP3A4 inhibitors or inducers within 2 weeks or 5 half-lives of the drug, whichever is shorter, prior to first dose on study\n* History of serious cardiovascular conditions within 6 months prior to first dose on study\n* Unresolved toxicities from prior therapy greater than Grade 1 (per CTCAE version 5.0) (with exceptions of alopecia, vitiligo, and ≤ Grade 2 peripheral neuropathy) prior to the first dose on study\n* History of drug-induced pneumonitis\u002Finterstitial lung disease\n* Confirmed loss of function mutation or deletion of Rb1 gene","ALL","18 Years",{"count":223,"type":224},380,"ESTIMATED","INTERVENTIONAL",[227,228],"PHASE1","PHASE2","This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-023 is an oral medication that inhibits cyclin-dependent kinase 4 (CDK4).",[231,232],"HR+\u002FHER2- Breast Cancer","HR+, HER2-, Advanced Breast Cancer","2026-04-28",{"date":235,"type":236},"2026-05-04","ACTUAL",{"date":238,"type":236},"2025-08-20",{"date":240,"type":224},"2030-08",{"name":5,"class":6},14]